Cargando…

CXCR7 receptors facilitate the progression of colon carcinoma within lung not within liver

BACKGROUND: Liver and lung metastases are the predominant cause of colorectal cancer (CRC)-related mortality. Chemokine-receptor pairs have a critical role in determining the metastatic progression of tumours. Our hypothesis was that disruption of CXCR7/CXCR7 ligands axis could lead to a decrease in...

Descripción completa

Detalles Bibliográficos
Autores principales:	Guillemot, E, Karimdjee-Soilihi, B, Pradelli, E, Benchetrit, M, Goguet-Surmenian, E, Millet, M-A, Larbret, F, Michiels, J-F, Birnbaum, D, Alemanno, P, Schmid-Antomarchi, H, Schmid-Alliana, A
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 2012
Materias:	Translational Therapeutics
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3516689/ https://www.ncbi.nlm.nih.gov/pubmed/23169289 http://dx.doi.org/10.1038/bjc.2012.503

Ejemplares similares

CXCR7-mediated progression of osteosarcoma in the lungs
por: Goguet-Surmenian, E, et al.
Publicado: (2013)

Organ-specific inhibition of metastatic colon carcinoma by CXCR3 antagonism
por: Cambien, B, et al.
Publicado: (2009)

CCL5 Neutralization Restricts Cancer Growth and Potentiates the Targeting of PDGFRβ in Colorectal Carcinoma
por: Cambien, Béatrice, et al.
Publicado: (2011)

Inhibition of CXCR4–CXCL12 chemotaxis in melanoma by AMD11070
por: O'Boyle, G, et al.
Publicado: (2013)

Inhibition of CXCR7 extends survival following irradiation of brain tumours in mice and rats
por: Walters, M J, et al.
Publicado: (2014)

CXCL12–CXCR4 signalling axis confers gemcitabine resistance to pancreatic cancer cells: a novel target for therapy
por: Singh, S, et al.
Publicado: (2010)

CXCR4 activation maintains a stem cell population in tamoxifen-resistant breast cancer cells through AhR signalling
por: Dubrovska, A, et al.
Publicado: (2012)

Idiopathic CD4 T Cell Lymphocytopenia: A Case of Overexpression of PD-1/PDL-1 and CTLA-4
por: Kumar, Gaurav, et al.
Publicado: (2021)

Dual inhibition of EGFR and mTOR pathways in small cell lung cancer
por: Schmid, K, et al.
Publicado: (2010)

Environmental signals perceived by the brain abate pro-metastatic monocytes by dampening glucocorticoids receptor signaling
por: Canali, María Magdalena, et al.
Publicado: (2023)

Novel role of pancreatic differentiation 2 in facilitating self-renewal and drug resistance of pancreatic cancer stem cells
por: Vaz, A P, et al.
Publicado: (2014)

Microtubule-associated protein tau facilitates the targeted killing of proliferating cancer cells in vitro and in a xenograft mouse tumour model in vivo
por: Hristodorov, D, et al.
Publicado: (2013)

Caspase-dependent and -independent suppression of apoptosis by monoHER in Doxorubicin treated cells
por: Bruynzeel, A M E, et al.
Publicado: (2007)

MTOR inhibitor-based combination therapies for pancreatic cancer
por: Hassan, Zonera, et al.
Publicado: (2018)

Understanding the Progression of Bone Metastases to Identify Novel Therapeutic Targets
por: Schmid-Alliana, Annie, et al.
Publicado: (2018)

Antitumour efficacy of MEK inhibitors in human lung cancer cells and their derivatives with acquired resistance to different tyrosine kinase inhibitors
por: Morgillo, F, et al.
Publicado: (2011)

Antiproliferative activity of PEP005, a novel ingenol angelate that modulates PKC functions, alone and in combination with cytotoxic agents in human colon cancer cells
por: Benhadji, K A, et al.
Publicado: (2008)

Monitoring response to cytostatic cisplatin in a HER2(+) ovary cancer model by MRI and in vitro and in vivo MR spectroscopy
por: Pisanu, M E, et al.
Publicado: (2014)

Intrinsic resistance to selumetinib, a selective inhibitor of MEK1/2, by cAMP-dependent protein kinase A activation in human lung and colorectal cancer cells
por: Troiani, T, et al.
Publicado: (2012)

The role of folate receptor alpha (FRα) in the response of malignant pleural mesothelioma to pemetrexed-containing chemotherapy
por: Nutt, J E, et al.
Publicado: (2010)

Detecting treatment response in a model of human breast adenocarcinoma using hyperpolarised [1-(13)C]pyruvate and [1,4-(13)C(2)]fumarate
por: Witney, T H, et al.
Publicado: (2010)

Anti-Cripto Mab inhibit tumour growth and overcome MDR in a human leukaemia MDR cell line by inhibition of Akt and activation of JNK/SAPK and bad death pathways
por: Hu, X F, et al.
Publicado: (2007)

N-(4-iodophenyl)-N′-(2-chloroethyl)urea as a microtubule disrupter: in vitro and in vivo profiling of antitumoral activity on CT-26 murine colon carcinoma cell line cultured and grafted to mice
por: Borel, M, et al.
Publicado: (2007)

Inhibition of formyl peptide receptor in high-grade astrocytoma by CHemotaxis Inhibitory Protein of S. aureus
por: Boer, J C, et al.
Publicado: (2013)

Anti-HER-2 DNA vaccine protects Syrian hamsters against squamous cell carcinomas
por: Berta, G N, et al.
Publicado: (2005)

Inhibition of tyrosine kinase receptors by SU6668 promotes abnormal stromal development at the periphery of carcinomas
por: Farace, P, et al.
Publicado: (2009)

CD44 targeting reduces tumour growth and prevents post-chemotherapy relapse of human breast cancers xenografts
por: Marangoni, E, et al.
Publicado: (2009)

Effects of oestrogens and anti-oestrogens on normal breast tissue from women bearing BRCA1 and BRCA2 mutations
por: Bramley, M, et al.
Publicado: (2006)

Safety and pharmacokinetics of paclitaxel and the oral mTOR inhibitor everolimus in advanced solid tumours
por: Campone, M, et al.
Publicado: (2009)

E. coli NfsA: an alternative nitroreductase for prodrug activation gene therapy in combination with CB1954
por: Vass, S O, et al.
Publicado: (2009)

Clinical significance of p95HER2 overexpression, PTEN loss and PI3K expression in p185HER2-positive metastatic breast cancer patients treated with trastuzumab-based therapies
por: Tural, D, et al.
Publicado: (2014)

Epigenetic remodelling of gene expression profiles of neoplastic and normal tissues: immunotherapeutic implications
por: Coral, S, et al.
Publicado: (2012)

In vitro synergistic cytotoxicity of gemcitabine and pemetrexed and pharmacogenetic evaluation of response to gemcitabine in bladder cancer patients
por: Mey, V, et al.
Publicado: (2006)

Interaction between gemcitabine and topotecan in human non-small-cell lung cancer cells: effects on cell survival, cell cycle and pharmacogenetic profile
por: Giovannetti, E, et al.
Publicado: (2005)

Image-guided and passively tumour-targeted polymeric nanomedicines for radiochemotherapy
por: Lammers, T, et al.
Publicado: (2008)

Antiproliferative effects of sapacitabine (CYC682), a novel 2′-deoxycytidine-derivative, in human cancer cells
por: Serova, M, et al.
Publicado: (2007)

Prevention of multidrug resistance (MDR) in osteosarcoma by NSC23925
por: Yang, X, et al.
Publicado: (2014)

Choline kinase-alpha by regulating cell aggressiveness and drug sensitivity is a potential druggable target for ovarian cancer
por: Granata, A, et al.
Publicado: (2014)

MGMT promoter hypermethylation and K-RAS, PTEN and TP53 mutations in tamoxifen-exposed and non-exposed endometrial cancer cases
por: Nagy, E, et al.
Publicado: (2014)

Identification of biomarkers for the antiangiogenic and antitumour activity of the superoxide dismutase 1 (SOD1) inhibitor tetrathiomolybdate (ATN-224)
por: Doñate, F, et al.
Publicado: (2008)

Cannot write session to /tmp/vufind_sessions/sess_uqdk0t8360u1461ve2lc1fatia